HUMA

4.56

3.40% 0.15

Vorhandelsmarkt: 4.54 -0.02 -0.44%

Humacyte Inc (HUMA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HUMA? Forum Prognose

Schlusskurs vom Vortag:

$4.41

Offen:

$4.45

24-Stunden-Volumen:

2.26M

Relative Volume:

0.48

Marktkapitalisierung:

$586.73M

Einnahmen:

Nettoeinkommen (Verlust:

$-110.78M

KGV:

-4.2617

EPS:

-1.07

Netto-Cashflow:

$-75.59M

1W Leistung:

+10.68%

1M Leistung:

-1.72%

6M Leistung:

-39.60%

1J Leistung:

+70.79%

1-Tages-Spanne:

$4.39

$4.615

1-Wochen-Bereich:

$4.02

$4.665

52-Wochen-Spanne:

$2.689

$9.97

Humacyte Inc Stock (HUMA) Company Profile

Firmenname

Humacyte Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (685)

Telefon

919-313-9633

Adresse

2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM

Mitarbeiter

185

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

HUMA's Discussions on Twitter

Vergleichen Sie HUMA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HUMA Humacyte Inc	4.56	586.73M	0	-110.78M	-75.59M	-1.07
VRTX Vertex Pharmaceuticals Inc	427.89	110.19B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	687.80	75.58B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	647.39	38.71B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	264.99	34.18B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	117.25	28.11B	3.30B	-501.07M	1.03B	-2.1146

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-20	Bestätigt	H.C. Wainwright	Buy
2023-12-11	Eingeleitet	H.C. Wainwright	Buy
2023-08-14	Hochstufung	Piper Sandler	Underweight → Neutral
2023-06-22	Eingeleitet	Cantor Fitzgerald	Overweight
2022-05-16	Herabstufung	Piper Sandler	Overweight → Underweight
2021-10-29	Eingeleitet	Cowen	Outperform
2021-09-24	Eingeleitet	Oppenheimer	Outperform
2021-09-22	Eingeleitet	BTIG Research	Buy
2021-09-16	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Humacyte Inc Aktie (HUMA) Neueste Nachrichten

Jan 21, 2025

DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire

Jan 21, 2025

DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.

Jan 21, 2025

Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat

Jan 21, 2025

Humacyte moves to test bioengineered vessel in heart surgery - Investing.com

Jan 21, 2025

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting - The Manila Times

Jan 21, 2025

Jan 20, 2025

11,105 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Brookstone Capital Management - Defense World

Jan 20, 2025

Jan 18, 2025

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Jan 17, 2025

HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire

Jan 17, 2025

HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - GlobeNewswire Inc.

Jan 17, 2025

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire

Jan 17, 2025

Cantor Fitzgerald Forecasts Stronger Earnings for Humacyte - MarketBeat

Jan 17, 2025

Humacyte, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsHUMA - PR Newswire

Jan 17, 2025

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider

Jan 17, 2025

Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, - GuruFocus.com

Jan 17, 2025

Jan 16, 2025

Shareholders that lost money on Humacyte, Inc.(HUMA) should - GlobeNewswire

Jan 16, 2025

Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update - MarketBeat

Jan 16, 2025